TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is planning preclinical studies that pair its PH1 spliceosome-modulating payload with Whitehawk Therapeutics' topoisomerase I inhibitor (TOP1i) ADC platform, CEO Abizer Gaslightwala said in a Virtual Investor "What This Means" interview.

TAMPA, FL – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is pairing its proprietary PH1 spliceosome-modulating payload with WhiteHawk Therapeutics' TOP1 inhibitor antibody drug conjugate (ADC) platform to test a dual-payload approach in oncology. President and CEO Abizer Gaslightwala laid out the rationale in a new CEO Corner segment released today. The release does not disclose financial terms.

Tampa – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) reported a second-quarter 2026 net loss of $4.8 million, up from $1.9 million a year earlier, as research and development spending tripled to $2.1 million ahead of a planned Phase 1 start for its lead antibody drug conjugate (ADC), AKTX-101, in mid-2027.

TAMPA – – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) reported that its TROP2-targeted ADC AKTX-101 slowed tumor growth in urothelial cancer models with limited response to Padcev or acquired resistance to Trodelvy. The company is targeting a Phase 1 start in mid-2027.

TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is targeting a First-In-Human trial of its lead antibody drug conjugate (ADC), AKTX-101, by mid-2027, after starting IND-enabling studies. The company laid out its investment case in the Virtual Investor "Why Now" on-demand conference.

CEO Abizer Gaslightwala argued that now is a pivotal time for Akari. He cited a fast-changing ADC landscape and rising industry demand for differentiated payload technologies.

TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) will present its PH1 antibody drug conjugate (ADC) payload at five oncology, ADC and investor conferences in the United States and China during September 2026, as it looks for pharma partners and investors ahead of a planned first-in-human trial by mid-2027.

CEO Abizer Gaslightwala will deliver a keynote and featured presentations. The company says it will discuss global R&D collaboration, platform partnerships and pipeline expansion.

TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) has filed international patent application PCT/US2026/45955, adding claims on how its PH1 payload modulates alternative splicing across multiple cancer-driving genes.

Tampa, FL and London – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) has appointed Vatnak Vat-Ho as Chief Business Officer, adding an executive who has held senior roles in oncology transactions totaling more than $25 billion in aggregate value.

TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) plans to begin Phase 1 clinical development of its lead antibody drug conjugate, AKTX-101, in mid-2027, with the compound now moving through IND-enabling toxicology and safety studies and large-scale GMP manufacturing.

CEO Abizer Gaslightwala laid out the strategy in a new CEO Corner segment. He argues that payload differentiation will matter more as ADCs move into front-line therapy and patients develop resistance to current payload classes, leaving few follow-on options.